▲ +46.61% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Zynex in the last 3 months. The average price target is $21.63, with a high forecast of $25.00 and a low forecast of $19.00. The average price target represents a 46.61% upside from the last price of $14.75.
The current consensus among 4 contributing investment analysts is to hold stock in Zynex. This rating has held steady since March 2020, when it changed from a Buy consensus rating.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.